IP Library Granted Patent US 12,239,623
Granted Patent B2
US 12,239,623 · App. 18/665,149 · Granted Mar 4, 2025

Sleep-improving compositions and methods of use

Inventors: James R. Komorowski (Trumbull, CT); Devon Bernsley (New York, NY)
Assignee: Bonafide Health, LLC
A61K31/198A61K31/197A61K31/235A61K31/685A61K31/7076A61K33/06A61P25/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,623
App. No.
18/665,149
Granted
Mar 4, 2025
Kind
B2
Abstract

Disclosed herein are compositions comprising two or more sleep-inducing agonists and/or a sleep-inducing antagonist. The compositions are for promoting healthy sleep quality and treating, ameliorating, preventing, or reducing one or more symptoms associated with menopause. Also described herein are methods utilizing the aforementioned compositions.

Claims (18)

1. A composition for promoting healthy sleep quality comprising two or more sleep-inducing agonists, wherein a first sleep-inducing agonist is L-theanine and a second sleep-inducing agonist is a magnesium salt, wherein L-theanine and the magnesium salt are present in a synergistic ratio of about 2:1 by weight.

2. The composition of claim 1 further comprises a sleep- inducing antagonist, wherein the sleep-inducing antagonist is S-adenosyl L-methionine (SAMe).

3. The composition of claim 1 , wherein the magnesium salt is magnesium glycinate.

4. The composition of claim 1 further comprises a third sleep-inducing agonist, wherein the third sleep-inducing agonist is gamma-aminobutyric acid (GABA).

5. The composition of claim 4 further comprises a brain- health supporting agent, wherein the brain-health supporting agent is phosphatidylserine.

6. The composition of claim 4 , wherein the composition further comprises a combination of a sleep-inducing antagonist and a gallic acid ester, wherein the sleep-inducing antagonist is S-adenosyl L-methionine (SAMe).

7. The composition of claim 6 , wherein the gallic acid ester is propyl gallate.

8. The composition of claim 7 further comprises a brain-health supporting agent, wherein the brain-health supporting agent is phosphatidylserine.

9. The composition of claim 1 further comprises a combination of a sleep-inducing antagonist and a gallic acid ester, wherein the sleep-inducing antagonist is S-adenosyl L-methionine (SAMe).

10. The composition of claim 9 , wherein the gallic acid ester is propyl gallate.

11. The composition of claim 10 further comprises a brain-health supporting agent, wherein the brain-health supporting agent is phosphatidylserine.

12. The composition of claim 2 , wherein wherein the composition further comprises propyl gallate.

13. The composition of claim 4 , wherein the amount of the magnesium salt, the amount of L-theanine, and the amount of GABA are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3 of the magnesium salt to L-theanine to GABA by weight, respectively.

14. The composition of claim 5 , wherein the amount of the magnesium salt, the amount of L-theanine, the amount of GABA, and the amount of phosphatidylserine are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3:1 of the magnesium salt to L-theanine to GABA to phosphatidylserine by weight, respectively.

15. The composition of claim 7 , wherein the amount of the magnesium salt, the amount of L-theanine, the amount of GABA, and the combined amount of SAMe and propyl gallate are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3:4.12 of the magnesium salt to L-theanine to GABA to the combination of SAMe and propyl gallate by weight, respectively.

16. The composition of claim 8 , wherein the amount of the magnesium salt, the amount of L-theanine, the amount of GABA, the combined amount of SAMe and propyl gallate, and the amount of phosphatidylserine are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3:4.125:1 of the magnesium salt to L-theanine to GABA to the combination of SAMe and propyl gallate to phosphatidylserine, respectively.

17. The composition of claim 10 , wherein the amount of the magnesium salt, the amount of L-theanine, and the combined amount of SAMe and propyl gallate are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:4.125 of the magnesium salt to L-theanine to the combination of SAMe and propyl gallate by weight, respectively.

18. The composition of claim 11 , wherein the amount of the magnesium salt, the amount of L-theanine, the combined amount of SAMe and propyl gallate, and the amount of phosphatidylserine are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:4.125:1 of the magnesium salt to L-theanine to the combination of SAMe and propyl gallate to phosphatidyl serine by weight, respectively.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2024
From: KOMOROWSKI, JAMES R.; BERNSLEY, DEVON
To: JDS THERAPEUTICS, LLC
Reel/Frame 067430/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2024
From: JDS THERAPEUTICS, LLC
To: BONAFIDE HEALTH, LLC
Reel/Frame 067430/0792 →